Clinical Trial Update: An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study [Phase 2]

View source ↗

Summary

This is a Phase 2 dose-ranging trial evaluating BAY59-7939 (rivaroxaban) as prophylaxis for venous thromboembolism after total knee replacement; the study has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• BAY59-7939 (rivaroxaban) (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED